Images
The Teaching Commission of the Higher Council of the University of Buenos Aires (UBA), in Argentina, has granted the title of doctor “honoris causa” to Fernando Albericio, leader of the Combinatorial Chemistry for the Discovery of New Compounds laboratory at IRB Barcelona, in recognition of his research and teaching activities over the course of his broad professional career.
The School of Pharmacy and Biochemistry of the UBA, which with Albericio maintains a close relationship through several collaboration agreements, put forward his name for this honor. This proposal highlights his work as a researcher—he has published over 550 scientific articles in international journals and presented more than 40 patents—and the excellence achieved in the academic world—he has directed more than 30 doctoral theses, some of them at the UBA, which have received a qualification of excellent cum laude. In addition, he has participated in over 150 international conferences and in committees and editorial boards of several internationally renowned scientific journals.
Fernando Albericio obtained his PhD in Chemical Sciences from the University of Barcelona in 1981, and, after several post-doctoral stays at Tufts University (United States), the Université d’Aix Marseilles (France), and the University of Minnesota, he returned to the University of Barcelona to take up a position of associate professor. Between 1992 and 1994 he was the director of peptide research at Milligen/Bioresearch (Boston, USA).
He currently combines his research activities at IRB Barcelona with his position at the University of Barcelona, where he is full professor of Organic Chemistry. Albericio also served as the director of the Barcelona Science Park from 2005 to 2012. In the past few years he has worked closely with the transfer of knowledge and technology to society and facilitated the set-up of biotech companies. He is a member of the administration boards of several foundations and companies and consultant to companies working in the chemistry and pharmaceutical sector.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
